Research progress on biomarkers related to the efficacy of neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma
10.3760/cma.j.cn113030-20210421-00169
- VernacularTitle:食管鳞癌新辅助放化疗疗效相关生物标志物的研究进展
- Author:
Xiaoli ZHENG
1
;
Ruidi JIAO
;
Yang YANG
;
Hong GE
Author Information
1. 郑州大学附属肿瘤医院/河南省肿瘤医院放疗科，郑州 450008
- Keywords:
Esophageal squamous cell carcinoma;
Neoadjuvant chemoradiotherapy;
Biomarker
- From:
Chinese Journal of Radiation Oncology
2022;31(10):949-954
- CountryChina
- Language:Chinese
-
Abstract:
Esophageal squamous cell carcinoma is one of the most common malignant tumors in China. Neoadjuvant chemoradiotherapy combined with surgery significantly improved the survival rate of locally advanced operable esophageal squamous cell carcinoma, but approximately half of the patients had poor or no efficacy. To accurately predict the efficacy of neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma and select the dominant population of neoadjuvant chemoradiotherapy, many studies on biomarkers have emerged, which have promoted the progress of neoadjuvant therapy for esophageal squamous cell carcinoma to some extent. In this article, the studies on biomarkers predicting the efficacy of neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma were reviewed.
